SG10201401661RA - Multicycle compounds and pharmaceutical compositions useful for the treatment of neurological disorders - Google Patents
Multicycle compounds and pharmaceutical compositions useful for the treatment of neurological disordersInfo
- Publication number
- SG10201401661RA SG10201401661RA SG10201401661RA SG10201401661RA SG10201401661RA SG 10201401661R A SG10201401661R A SG 10201401661RA SG 10201401661R A SG10201401661R A SG 10201401661RA SG 10201401661R A SG10201401661R A SG 10201401661RA SG 10201401661R A SG10201401661R A SG 10201401661RA
- Authority
- SG
- Singapore
- Prior art keywords
- multicycle
- compounds
- treatment
- pharmaceutical compositions
- neurological disorders
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/76—Dibenzothiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26688009P | 2009-12-04 | 2009-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201401661RA true SG10201401661RA (en) | 2014-07-30 |
Family
ID=44115515
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012040895A SG181498A1 (en) | 2009-12-04 | 2010-12-03 | Multicyclic compounds and methods of use thereof |
SG10201510665WA SG10201510665WA (en) | 2009-12-04 | 2010-12-03 | Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders |
SG10201401661RA SG10201401661RA (en) | 2009-12-04 | 2010-12-03 | Multicycle compounds and pharmaceutical compositions useful for the treatment of neurological disorders |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012040895A SG181498A1 (en) | 2009-12-04 | 2010-12-03 | Multicyclic compounds and methods of use thereof |
SG10201510665WA SG10201510665WA (en) | 2009-12-04 | 2010-12-03 | Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders |
Country Status (19)
Country | Link |
---|---|
US (7) | US8710245B2 (en) |
EP (2) | EP2507245B1 (en) |
JP (7) | JP5778168B2 (en) |
KR (7) | KR101772834B1 (en) |
CN (4) | CN102762575B (en) |
AU (3) | AU2010325925B2 (en) |
BR (2) | BR122021013836B1 (en) |
CA (1) | CA2781716A1 (en) |
DK (1) | DK2507245T3 (en) |
ES (1) | ES2625330T3 (en) |
HK (2) | HK1212969A1 (en) |
IL (6) | IL272376B1 (en) |
MX (2) | MX2012006326A (en) |
NZ (5) | NZ767139A (en) |
PT (1) | PT2507245T (en) |
RU (3) | RU2641648C1 (en) |
SG (3) | SG181498A1 (en) |
WO (1) | WO2011069063A2 (en) |
ZA (1) | ZA201203533B (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ767139A (en) | 2009-12-04 | 2022-08-26 | Sunovion Pharmaceuticals Inc | Multicyclic compounds and methods of use thereof |
WO2013066152A1 (en) * | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Method for improving executive function |
CA2864085C (en) | 2012-02-08 | 2021-11-23 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
CN103755727B (en) * | 2013-12-20 | 2015-12-30 | 南京华威医药科技开发有限公司 | Preparation method of brinzolamide intermediate |
US20150202186A1 (en) * | 2014-01-23 | 2015-07-23 | Sova Pharmaceuticals, Inc. | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN |
CN104193722A (en) * | 2014-08-27 | 2014-12-10 | 湖南华腾制药有限公司 | Preparation method of N-tert-butyloxycarbonyl-3-methylaminothiophene |
MA48048A (en) * | 2014-08-27 | 2020-02-12 | Prexton Therapeutics Sa | NEW CHROMONE OXIME AND ITS USE AS AN ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTOR |
NZ734972A (en) * | 2015-02-11 | 2023-07-28 | Sunovion Pharmaceuticals Inc | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders |
JP6657241B2 (en) * | 2015-02-11 | 2020-03-04 | サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. | 1-Heterocyclic isochromanyl compounds and analogs for treating CNS diseases |
TN2018000061A1 (en) | 2015-08-27 | 2019-07-08 | Prexton Therapeutics Sa | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia |
JO3638B1 (en) * | 2015-09-09 | 2020-08-27 | Lilly Co Eli | Compounds useful for inhibiting ror-gamma-t |
EP3838274B1 (en) * | 2016-01-26 | 2023-11-01 | Intra-Cellular Therapies, Inc. | Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivative for use in the treatment of cns disorders |
WO2017144341A1 (en) | 2016-02-23 | 2017-08-31 | Bayer Cropscience Aktiengesellschaft | Condensed bicyclic heterocycle derivatives as pest control agents |
CN116514761A (en) | 2016-07-29 | 2023-08-01 | 赛诺维信制药公司 | Compounds, compositions and uses thereof |
AU2017301767A1 (en) | 2016-07-29 | 2019-02-14 | Pgi Drug Discovery Llc | Compounds and compositions and uses thereof |
CN110678205B (en) * | 2017-02-16 | 2023-05-23 | 桑诺维恩药品公司 | Method for treating schizophrenia |
WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
AU2018312559B2 (en) | 2017-08-02 | 2022-06-02 | Pgi Drug Discovery Llc | Isochroman compounds and uses thereof |
MX2020008537A (en) * | 2018-02-16 | 2021-01-08 | Sunovion Pharmaceuticals Inc | Salts, crystal forms, and production methods thereof. |
WO2019161236A1 (en) | 2018-02-16 | 2019-08-22 | Sunovion Pharmaceuticals Inc. | Methods of treating social function disorders |
WO2020118032A1 (en) | 2018-12-06 | 2020-06-11 | Sunovion Pharmaceuticals Inc. | Methods of treating neurological and psychiatric disorders |
EP3938045A1 (en) | 2019-03-14 | 2022-01-19 | Sunovion Pharmaceuticals Inc. | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
CN110894195A (en) * | 2019-12-09 | 2020-03-20 | 门希国 | Novel preparation method of 2-thiopheneacetic acid |
US20230147129A1 (en) | 2020-03-27 | 2023-05-11 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of synucleinopathies |
EP4135690A1 (en) | 2020-04-14 | 2023-02-22 | Sunovion Pharmaceuticals Inc. | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders |
EP4214212A1 (en) * | 2020-09-16 | 2023-07-26 | Teva Pharmaceuticals International GmbH | Solid state forms of sep-363856 and process for preparation thereof |
JP2024511828A (en) * | 2021-03-29 | 2024-03-15 | シューチン バイオファーマ カンパニー リミテッド | Spiro ring-containing derivatives, their preparation and use |
AU2022254568A1 (en) * | 2021-04-10 | 2023-11-16 | Sumitomo Pharma Co., Ltd. | Bicyclic pyridine derivative |
CN115677718A (en) * | 2021-07-30 | 2023-02-03 | 武汉思瓴生物科技有限公司 | Methylmethylamine derivative preparation, pharmaceutical composition and application thereof |
WO2023049721A1 (en) | 2021-09-23 | 2023-03-30 | Sunovion Pharmaceuticals Inc. | Methods of treating metabolic disorders |
WO2023078392A1 (en) * | 2021-11-04 | 2023-05-11 | 上海翰森生物医药科技有限公司 | 2-(aryl-2-yl) morpholine and deuterated derivative thereof, preparation method therefor and application thereof |
CN114324369B (en) * | 2022-03-11 | 2022-06-07 | 北京新研创能科技有限公司 | System and method for detecting scratches on surface of bipolar plate |
WO2023246872A1 (en) * | 2022-06-24 | 2023-12-28 | 山东绿叶制药有限公司 | Heterocyclic compound as taar1 ligand agonist |
WO2024050323A1 (en) | 2022-08-30 | 2024-03-07 | Sunovion Pharmaceuticals Inc. | Ulotaront for the adjuvant treatment of major depressive disorder |
WO2024067542A1 (en) * | 2022-09-27 | 2024-04-04 | 上海枢境生物科技有限公司 | Spirocyclic derivative-containing salt or crystal form, and preparation method therefor and use thereof |
WO2024081828A1 (en) | 2022-10-13 | 2024-04-18 | Sunovion Pharmaceuticals Inc. | Methods of reducing physical dependence to neuropsychiatric treatments |
CN115677719A (en) * | 2022-10-27 | 2023-02-03 | 复旦大学 | Aryl heterocyclic compound and preparation method and application thereof |
Family Cites Families (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US402145A (en) * | 1889-04-30 | Combined trough and rack | ||
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US4021451A (en) * | 1972-05-16 | 1977-05-03 | American Home Products Corporation | Process for preparing polycyclic heterocycles having a pyran ring |
US4036842A (en) * | 1972-05-16 | 1977-07-19 | American Home Products Corporation | Process for preparing polycyclic heterocycles having a pyran ring |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4021452A (en) | 1975-04-23 | 1977-05-03 | American Cyanamid Company | 2,5-Dihydro-2,5-dialkoxyfuran derivatives |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4127665A (en) | 1978-01-18 | 1978-11-28 | Pfizer Inc. | Thienohydantoin derivatives |
US4147797A (en) * | 1978-08-11 | 1979-04-03 | Pfizer Inc. | Spiro-furanohydantoin derivatives |
FR2459239A1 (en) * | 1979-06-20 | 1981-01-09 | Logeais Labor Jacques | NOVEL AMINO DERIVATIVES OF BENZOTHIAZOLE, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION |
GB8333512D0 (en) * | 1983-12-16 | 1984-01-25 | Erba Farmitalia | Tetrahydropyrano derivatives |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
NZ219646A (en) * | 1986-03-27 | 1990-10-26 | Merck Sharp & Dohme | Oxadiazole derivatives of azacyclics for treating cns disorders |
PH30676A (en) | 1986-07-22 | 1997-09-16 | Boehringer Ingelhein Kg | Hetrazepine compounds which have useful pharmaceutical utility |
NZ228331A (en) | 1988-03-16 | 1991-10-25 | Zambeletti Spa L | Amine- and amido-containing heterocyclic compounds and pharmaceutical compositions |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
DE3827727A1 (en) | 1988-08-16 | 1990-02-22 | Boehringer Ingelheim Kg | ANALYZED TETRAHYDROPYRIDINE IGNESE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE OF SUCH CONNECTIONS FOR CARDIRO PROTECTION |
GB8824400D0 (en) | 1988-10-18 | 1988-11-23 | Glaxo Group Ltd | Chemical compounds |
EP0368175A1 (en) * | 1988-11-06 | 1990-05-16 | Boehringer Ingelheim Kg | 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine. |
GB8827479D0 (en) | 1988-11-24 | 1988-12-29 | Zambeletti Spa L | Novel compounds |
IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
EP0416740A3 (en) | 1989-08-08 | 1991-08-28 | Beecham Group P.L.C. | Novel compounds with renin-inhibiting activity |
JPH0735373B2 (en) | 1989-08-11 | 1995-04-19 | 三共株式会社 | Carboxamide compound |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
GB8926560D0 (en) | 1989-11-24 | 1990-01-17 | Zambeletti Spa L | Pharmaceuticals |
US5032598A (en) | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents |
GB8927872D0 (en) | 1989-12-08 | 1990-02-14 | Beecham Group Plc | Pharmaceuticals |
JPH03223277A (en) | 1989-12-29 | 1991-10-02 | Yoshitomi Pharmaceut Ind Ltd | Benzothiophene derivative |
KR0166088B1 (en) | 1990-01-23 | 1999-01-15 | . | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
ZA912744B (en) | 1990-03-23 | 1992-02-26 | Zambeletti Spa L | Pharmaceuticals |
JPH049367A (en) | 1990-04-26 | 1992-01-14 | Zeria Pharmaceut Co Ltd | Arylalkanoyl derivative, production intermediate for the compound and drug containing the same |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
GB9018139D0 (en) * | 1990-08-17 | 1990-10-03 | Pfizer Ltd | Therapeutic agents |
NZ240155A (en) | 1990-10-29 | 1992-10-28 | Ishihara Sangyo Kaisha | Heterocyclyl acyl and (hexahydro) indanyl acyl substituted hydrazine derivatives, preparation thereof and pesticidal compositions |
DE4104257A1 (en) | 1991-02-13 | 1992-08-20 | Boehringer Ingelheim Kg | USE OF ANALYZED TETRAHYDROPYRIDINE IGNESE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL ILLNESSES |
GB9104839D0 (en) | 1991-03-07 | 1991-04-17 | Zambeletti Spa L | Novel compounds |
NZ243065A (en) | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
PH31294A (en) | 1992-02-13 | 1998-07-06 | Thomae Gmbh Dr K | Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them. |
JP3223277B2 (en) | 1992-04-10 | 2001-10-29 | カシオ計算機株式会社 | Music control device |
FR2692264B1 (en) | 1992-06-12 | 1994-08-05 | Adir | NOVEL 1,4-DISUBSTITUTED PIPERAZINES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
IT1255178B (en) | 1992-06-26 | 1995-10-20 | Pierrel Spa | N (ETER0) -ARIL-N (ETERO) -TETRALINALCHIL PIPERAZINE HAVING SEROTONINERGIC, DOPAMINERGIC AND ADRENERGIC ACTIVITIES |
ATE169179T1 (en) | 1992-12-02 | 1998-08-15 | Ciba Geigy Ag | SELECTIVE HERBICIDES |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
TW334423B (en) * | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
JP3163068B2 (en) | 1993-12-27 | 2001-05-08 | 日本建工株式会社 | Field edge mounting bracket |
IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
FR2723091B1 (en) | 1994-07-29 | 1996-11-08 | Esteve Labor Dr | TETRAHYDROPYRIDINE- (6,4-HYDROXYPIPERIDINE) ALKYLAZOLES |
FR2734819B1 (en) | 1995-05-31 | 1997-07-04 | Adir | NOVEL COMPOUNDS OF PIPERAZINE, PIPERIDINE AND 1,2,5,6-TETRAHYDROPYRIDINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
HUP0102612A2 (en) | 1998-03-12 | 2001-11-28 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases |
WO1999046267A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
US6262044B1 (en) * | 1998-03-12 | 2001-07-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPASES) |
IL138319A0 (en) * | 1998-03-12 | 2001-10-31 | Novo Nordisk As | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
EP1123292A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
TR200101649T2 (en) | 1998-12-14 | 2001-10-22 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives. |
ATE328887T1 (en) | 1999-01-19 | 2006-06-15 | Neurosearch As | CONDENSED HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
US6313309B1 (en) * | 1999-04-05 | 2001-11-06 | Ortho-Mcneil Pharmaceutical, Inc. | 4-thionaphthyl—1H—imidazoles which are usefulα22-adrenoceptoR agonists/ antagonists |
AU4589800A (en) | 1999-05-05 | 2000-11-21 | Darwin Discovery Limited | 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors |
ATE313322T1 (en) | 1999-07-02 | 2006-01-15 | Warner Lambert Co | SYNERGISTIC COMBINATION: GABAPENTIN AND PREGABALIN |
ATE309250T1 (en) | 1999-09-10 | 2005-11-15 | Novo Nordisk As | MODULATORS OF PROTEIN TYROSINE PHOSPHATASE (PTPASES) |
WO2001017516A2 (en) | 1999-09-10 | 2001-03-15 | Novo Nordisk A/S | Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48 |
WO2001032610A1 (en) | 1999-10-29 | 2001-05-10 | Kaken Pharmaceutical Co., Ltd. | Urea derivative, process for producing the same, and medicine containing the urea derivative |
AR030537A1 (en) | 1999-11-05 | 2003-08-27 | Abbott Lab | ANTIBACTERIAL CHINOLINCARBOXILIC AND NAFTIRIDINCARBOXILIC ACIDS |
ATE253918T1 (en) * | 1999-12-08 | 2003-11-15 | Centre Nat Rech Scient | USE OF HYMENIALDISINE AND ITS DERIVATIVES FOR THE PRODUCTION OF THERAPEUTIC AGENTS |
US7112594B2 (en) | 2000-08-09 | 2006-09-26 | Mitsubishi Pharma Corporation | Fused bicyclic amide compounds and medicinal use thereof |
WO2002022614A1 (en) | 2000-09-12 | 2002-03-21 | Sankyo Company,Limited | Quinolizine derivatives |
WO2002102387A1 (en) | 2001-06-18 | 2002-12-27 | H. Lundbeck A/S | Treatment of neuropathic pain |
WO2003006455A1 (en) * | 2001-07-11 | 2003-01-23 | Eli Lilly And Company | Pharmaceutical compounds with serotonin receptor activity |
US20040180883A1 (en) * | 2001-07-11 | 2004-09-16 | Jeremy Gilmore | Pharmaceutical compounds with serotonin receptor activity |
EP1441725A1 (en) | 2001-10-26 | 2004-08-04 | Aventis Pharmaceuticals Inc. | Benzimidazoles and analogues and their use as protein kinases inhibitors |
JP2003261566A (en) | 2002-03-11 | 2003-09-19 | Sankyo Co Ltd | Medicament containing quinolizine |
TW200930291A (en) | 2002-04-29 | 2009-07-16 | Bayer Cropscience Ag | Pesticidal heterocycles |
US7323485B2 (en) | 2002-05-21 | 2008-01-29 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7358269B2 (en) | 2002-05-21 | 2008-04-15 | Allergan, Inc. | 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one |
US7276522B2 (en) | 2002-05-21 | 2007-10-02 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
SE0202134D0 (en) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Therapeutic agents |
EP1554394B1 (en) | 2002-10-16 | 2009-12-16 | Isis Innovation Limited | Screening methods using a structural model of FIH |
DE10252667A1 (en) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | New spiro-((cyclohexane)-tetrahydropyrano-(3,4-b)-indole) derivatives, are ORL1 receptor ligands useful e.g. for treating anxiety, depression, epilepsy, senile dementia, withdrawal symptoms or especially pain |
CA2506016C (en) * | 2002-11-21 | 2009-03-17 | Pfizer Products Inc. | 3-amino-piperidine derivatives and processes for their preparation |
US20060241130A1 (en) | 2003-01-31 | 2006-10-26 | Ehud Keinan | Anti-inflammatory compositions and uses thereof |
TWI422583B (en) | 2003-03-07 | 2014-01-11 | 參天製藥股份有限公司 | Novel compound having 4-pyridylalkylthio group as substituent |
JP2004269449A (en) | 2003-03-11 | 2004-09-30 | Ishihara Sangyo Kaisha Ltd | Benzamide derivative, method for producing the same, and pest-controlling agent containing the same |
US7205318B2 (en) | 2003-03-18 | 2007-04-17 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors |
EP1611109A4 (en) | 2003-03-31 | 2009-06-24 | Taisho Pharmaceutical Co Ltd | Novel quinazoline derivatives and methods of treatment related to the use thereof |
JP2005145859A (en) | 2003-11-13 | 2005-06-09 | Nippon Steel Chem Co Ltd | Dehydrogenation method and method for producing aromatic heterocyclic compound |
DE10360793A1 (en) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclic cyclohexane derivatives |
US20060019952A1 (en) | 2004-01-29 | 2006-01-26 | Elixir Pharmaceuticals, Inc. | Anti-viral therapeutics |
DE102004004974A1 (en) | 2004-01-31 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Thieno-imino acid derivatives as inhibitors of matrix metalloproteinases |
KR100553398B1 (en) * | 2004-03-12 | 2006-02-16 | 한미약품 주식회사 | METHOD OF PREPARING THIENO [3,2-c]PYRIDINE DERIVATIVES AND INTERMEDIATES USED THEREIN |
AU2005267798A1 (en) | 2004-07-28 | 2006-02-09 | Irm Llc | Compounds and compositions as modulators of steroid hormone nuclear receptors |
SE0401971D0 (en) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
SE0401970D0 (en) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Novel compounds |
EP1634873A1 (en) * | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
FR2875230A1 (en) | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | CONDENSED PYRAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
JP2006117568A (en) | 2004-10-20 | 2006-05-11 | Mitsubishi Pharma Corp | New amide derivative having thiophene ring and its application as medicine |
WO2006053274A2 (en) | 2004-11-15 | 2006-05-18 | Bristol-Myers Squibb Company | 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
WO2006089053A2 (en) | 2005-02-17 | 2006-08-24 | Wyeth | Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives |
CA2605594A1 (en) | 2005-04-22 | 2006-11-02 | Daiichi Sankyo Company, Limited | Heterocyclic compound |
JP2008546898A (en) | 2005-06-27 | 2008-12-25 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | Conductive polymer composition |
WO2007001939A1 (en) | 2005-06-27 | 2007-01-04 | Janssen Pharmaceutica N.V. | Tetrahydro-pyranopyrazole compounds displaying cannabinoid modulating activities |
WO2007006546A1 (en) | 2005-07-11 | 2007-01-18 | Devgen N.V. | Amide derivatives as kinase inhibitors |
US8846742B2 (en) | 2006-02-14 | 2014-09-30 | The Trustees Of Columbia University In The City Of New York | Neuronal pain pathway modulators |
US20090264470A1 (en) | 2006-02-21 | 2009-10-22 | Bennett Teresa A | CB1 Antagonists and Inverse Agonists |
EP1829869A1 (en) * | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands |
US20090318690A1 (en) | 2006-04-28 | 2009-12-24 | Eisai R&D Management Co., Ltd. | Benzisoxazole Compound |
AU2007305269A1 (en) | 2006-10-04 | 2008-04-10 | Schering Corporation | Bicyclic and tricyclic derivatives as thrombin receptor antagonists |
US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
AU2007321720A1 (en) | 2006-11-15 | 2008-05-22 | Genetic Technologies Limited | Compounds, compositions and methods for controlling invertebrate pests |
WO2009008906A2 (en) | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Therapeutic compounds for blocking dna synthesis of pox viruses |
US7598417B2 (en) | 2007-04-12 | 2009-10-06 | Allergan, Inc. | Substituted fluoroethyl ureas as alpha 2 adrenergic agents |
EP1982714A1 (en) * | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Pyrano-pyrazole-amines |
EP1982987A1 (en) | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Spiro-pyrano-pyrazole derivatives |
EP2020414A1 (en) * | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
US8338623B2 (en) | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
JP2011504499A (en) | 2007-11-21 | 2011-02-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Spiropiperidine for use as a tryptase inhibitor |
US7973051B2 (en) | 2007-11-30 | 2011-07-05 | Hoffman-La Roche Inc. | Aminothiazoles as FBPase inhibitors for diabetes |
US8268754B2 (en) | 2007-12-07 | 2012-09-18 | Nissan Chemical Industries, Ltd. | Substituted dihydroazole compound and pest control agent |
WO2009085256A1 (en) | 2007-12-27 | 2009-07-09 | Panacos Pharmaceuticals, Inc. | Anti-hiv compounds |
CN101759710B (en) | 2008-10-06 | 2011-10-05 | 山东轩竹医药科技有限公司 | Cephalosporin derivatives containing substitutional nitrogen heterocycle |
US9776963B2 (en) | 2008-11-10 | 2017-10-03 | The Trustees Of The University Of Pennsylvania | Small molecule CD4 mimetics and uses thereof |
AR075442A1 (en) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY |
TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
WO2011036889A1 (en) | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | Heterocyclic compound |
MX2012005690A (en) * | 2009-11-16 | 2012-06-13 | Lilly Co Eli | Spiropiperidine compounds as orl-1 receptor antagonists. |
UA107943C2 (en) * | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Compounds of spiropiperidines as antagonists of the orl-1 receptors |
NZ767139A (en) | 2009-12-04 | 2022-08-26 | Sunovion Pharmaceuticals Inc | Multicyclic compounds and methods of use thereof |
US8796320B2 (en) | 2009-12-28 | 2014-08-05 | General Incorporated Association Pharma Valley Project Supporting Organization | 1,3,4-Oxadiazole-2-carboxamide compound |
EP2377850A1 (en) | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
EP2560636A4 (en) | 2010-04-23 | 2013-11-27 | Kineta Inc | Anti-viral compounds |
US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
EP2683710B1 (en) | 2011-03-10 | 2017-07-19 | Boehringer Ingelheim International GmbH | Soluble guanylate cyclase activators |
CN102731574B (en) | 2011-03-30 | 2016-03-02 | 中国人民解放军军事医学科学院毒物药物研究所 | Thienopyridines α-amido benzyl phosphonic acid ester, Preparation Method And The Use |
WO2013010453A1 (en) | 2011-07-15 | 2013-01-24 | Abbott Laboratories | Chemoking receptor antagonists |
KR101920169B1 (en) | 2014-07-23 | 2018-11-19 | 샤프 가부시키가이샤 | Display device and drive method for same |
CN110678205B (en) | 2017-02-16 | 2023-05-23 | 桑诺维恩药品公司 | Method for treating schizophrenia |
MX2020008537A (en) | 2018-02-16 | 2021-01-08 | Sunovion Pharmaceuticals Inc | Salts, crystal forms, and production methods thereof. |
WO2019161236A1 (en) | 2018-02-16 | 2019-08-22 | Sunovion Pharmaceuticals Inc. | Methods of treating social function disorders |
WO2020118032A1 (en) | 2018-12-06 | 2020-06-11 | Sunovion Pharmaceuticals Inc. | Methods of treating neurological and psychiatric disorders |
-
2010
- 2010-12-03 NZ NZ767139A patent/NZ767139A/en unknown
- 2010-12-03 KR KR1020167017387A patent/KR101772834B1/en active IP Right Grant
- 2010-12-03 CN CN201080062822.2A patent/CN102762575B/en active Active
- 2010-12-03 BR BR122021013836-2A patent/BR122021013836B1/en active IP Right Grant
- 2010-12-03 SG SG2012040895A patent/SG181498A1/en unknown
- 2010-12-03 NZ NZ600008A patent/NZ600008A/en unknown
- 2010-12-03 MX MX2012006326A patent/MX2012006326A/en active IP Right Grant
- 2010-12-03 KR KR1020127017294A patent/KR101637247B1/en active IP Right Grant
- 2010-12-03 BR BR112012013431-0A patent/BR112012013431B1/en active IP Right Grant
- 2010-12-03 US US13/513,176 patent/US8710245B2/en active Active
- 2010-12-03 CA CA2781716A patent/CA2781716A1/en active Pending
- 2010-12-03 KR KR1020177023257A patent/KR101855471B1/en active IP Right Grant
- 2010-12-03 JP JP2012542219A patent/JP5778168B2/en active Active
- 2010-12-03 DK DK10835185.9T patent/DK2507245T3/en active
- 2010-12-03 RU RU2015119926A patent/RU2641648C1/en active
- 2010-12-03 CN CN202010422479.3A patent/CN111560025A/en active Pending
- 2010-12-03 AU AU2010325925A patent/AU2010325925B2/en active Active
- 2010-12-03 RU RU2012127770/04A patent/RU2557059C2/en active
- 2010-12-03 IL IL272376A patent/IL272376B1/en unknown
- 2010-12-03 NZ NZ711802A patent/NZ711802A/en unknown
- 2010-12-03 KR KR1020187012385A patent/KR102074089B1/en active IP Right Grant
- 2010-12-03 KR KR1020217030661A patent/KR102505085B1/en active IP Right Grant
- 2010-12-03 RU RU2018100098A patent/RU2707067C2/en active
- 2010-12-03 PT PT108351859T patent/PT2507245T/en unknown
- 2010-12-03 EP EP10835185.9A patent/EP2507245B1/en active Active
- 2010-12-03 EP EP17160203.0A patent/EP3252057B1/en active Active
- 2010-12-03 KR KR1020157019665A patent/KR101637246B1/en active IP Right Grant
- 2010-12-03 SG SG10201510665WA patent/SG10201510665WA/en unknown
- 2010-12-03 WO PCT/US2010/058884 patent/WO2011069063A2/en active Application Filing
- 2010-12-03 SG SG10201401661RA patent/SG10201401661RA/en unknown
- 2010-12-03 CN CN201610836552.5A patent/CN106883246B/en active Active
- 2010-12-03 KR KR1020207002216A patent/KR102307413B1/en active IP Right Grant
- 2010-12-03 NZ NZ731621A patent/NZ731621A/en unknown
- 2010-12-03 NZ NZ626068A patent/NZ626068A/en unknown
- 2010-12-03 CN CN201410333332.1A patent/CN104193761B/en active Active
- 2010-12-03 ES ES10835185.9T patent/ES2625330T3/en active Active
-
2012
- 2012-05-15 ZA ZA2012/03533A patent/ZA201203533B/en unknown
- 2012-06-01 MX MX2020012825A patent/MX2020012825A/en unknown
- 2012-06-04 IL IL220173A patent/IL220173A0/en active IP Right Grant
-
2014
- 2014-03-12 US US14/205,859 patent/US9351954B2/en active Active
- 2014-12-15 JP JP2014253082A patent/JP5710064B1/en active Active
-
2015
- 2015-06-09 HK HK15105471.0A patent/HK1212969A1/en unknown
- 2015-07-08 JP JP2015136603A patent/JP6005807B2/en active Active
- 2015-11-24 US US14/950,834 patent/US10085968B2/en active Active
- 2015-12-10 IL IL243015A patent/IL243015B/en active IP Right Grant
- 2015-12-10 IL IL243021A patent/IL243021B/en active IP Right Grant
- 2015-12-10 IL IL243019A patent/IL243019B/en active IP Right Grant
- 2015-12-10 IL IL243018A patent/IL243018B/en active IP Right Grant
-
2016
- 2016-01-27 AU AU2016200448A patent/AU2016200448C1/en active Active
- 2016-07-01 JP JP2016131247A patent/JP6028310B1/en active Active
- 2016-09-29 JP JP2016191898A patent/JP6297655B2/en active Active
-
2017
- 2017-10-20 AU AU2017248551A patent/AU2017248551B2/en active Active
-
2018
- 2018-02-21 JP JP2018028819A patent/JP2018104454A/en active Pending
- 2018-05-31 HK HK18107195.8A patent/HK1247911A1/en unknown
- 2018-08-30 US US16/117,450 patent/US20190125722A1/en not_active Abandoned
-
2020
- 2020-02-14 US US16/791,118 patent/US10894033B2/en active Active
- 2020-06-24 JP JP2020108727A patent/JP7104746B2/en active Active
- 2020-11-19 US US16/952,401 patent/US20210267938A1/en not_active Abandoned
-
2022
- 2022-01-13 US US17/574,702 patent/US20220387382A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201510665WA (en) | Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders | |
HK1253046A1 (en) | Heterocyclic compounds for the treatment of neurological and psychological disorders | |
IL257581A (en) | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
GB201001047D0 (en) | Methods and compositions for the treatment of neurological disorders | |
EP2552433A4 (en) | Compositions and methods for the treatment of somatosensory disorders | |
LT2303330T (en) | Pharmaceutical compositions for treatment of parkinson`s disease | |
PL2318035T3 (en) | Methods and compositions for the treatment of symptoms of neurological and mental health disorders | |
IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
EP2528603A4 (en) | Pharmaceutical compositions for the treatment of pain and other indicatons | |
PT2300614E (en) | Methods and compositions for treatment of mitochondrial disorders | |
ZA201200944B (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
PT2429507T (en) | Phosphate-free pharmaceutical composition for the treatment of glaucoma | |
EP2213303A4 (en) | Pharmaceutical composition for treatment of cataract | |
HU0900231D0 (en) | Compositions for the treatment of allergic disorders | |
EP2612668A4 (en) | Pharmaceutical composition for the prevention or treatment of degenerative neurological brain disorders | |
IL200753A (en) | Pharmaceutical composition comprising ib-meca for the treatment of psoriasis | |
PT2344166E (en) | Pharmaceutical composition for the treatment of gastrointestinal irritation disorders | |
EP2212246B1 (en) | Treatment of neurological disorders | |
IL219050A0 (en) | Pharmaceutical composition for the treatment of bladder disorders | |
EP2329824A4 (en) | Novel pharmaceutical composition for treatment of nociceptive pain | |
IL199979A0 (en) | Pharmaceutical compositions for treatments of neurological disorders | |
HU0900722D0 (en) | Compounds for the treatment of neurological disorders |